

In the Specification:

Please amend the specification as shown:

Please delete paragraph [0035] and replace it with the following paragraph:

[0035] Figure 1. DNA and amino acid sequences of the murine LL1 heavy and light chain variable regions. Figure 1A shows DNA (SEQ ID NO: 1) and amino acid sequences (SEQ ID NO: 2) of LL1VH. Figure 1B shows DNA (SEQ ID NO: 3) and amino acid sequences (SEQ ID NO: 4) of the LL1V_k. Amino acid sequences encoded by the corresponding DNA sequences are given as one-letter codes below the nucleotide sequence. Numbering of the nucleotide sequence is on the right side. The amino acid residues in the CDR regions are shown in bold and underlined. Kabat's Ig molecule numbering is used for amino acid residues as shown by the numbering above the amino acid residues. The residues numbered by a letter following a particular digit indicates the insertion residues defined by Kabat numbering scheme. The insertion residues numbered with a letter have the same preceding digit. For example, residues 82A, 82B and 82C in Figure 1A are indicated as 82A, B, and C.

Please delete paragraph [0036] and replace it with the following paragraph:

[0036] Figure 2. DNA and amino acid sequences of chimeric LL1 (cLL1) heavy and light chain variable region. (See, U.S. Serial No. 10/377,122.) Figure 2A shows DNA (SEQ ID NO: 5) and amino acid sequences (SEQ ID NO: 6) of cLL1VH. Figure 2B shows double-stranded DNA (SEQ ID NO: 7) and amino acid sequences (SEQ ID NO: 8) of cLL1V_k. Amino acid sequences encoded by the corresponding DNA sequences are given as one-letter codes. The amino acid residues in the CDR regions are shown in bold and underlined. The numbering of nucleotides and amino acids is same as that in Figure 1.

Please delete paragraph [0037] and replace it with the following paragraph:

[0037] Figure 3. Alignment of amino acid sequences of light and heavy chain variable regions of a human antibody, cLL1 and hLL1. Figure 3A shows the VH amino acid sequence alignment of the human antibody RF-TS3 (SEQ ID NO: 13), cLL1 (SEQ ID NO: 6), and hLL1 (SEQ ID NO: 10), and NEWM (SEQ ID NO: 14) and Figure 3B shows the Vk amino acid sequence alignment of the human antibody HF-21/28 (SEQ ID NO: 15), cLL1 (SEQ ID NO: 8) and hLL1 (SEQ ID NO: 12). Dots indicate the residues in cLL1 that are identical to the corresponding residues in the human antibodies. Boxed regions represent the CDR regions. Both N- and C-terminal residues (underlined) of cLL1 are fixed by the staging vectors used and not compared with the human antibodies. Kabat's Ig molecule number scheme is used as in Figure 1.

Please delete paragraph [0038] and replace it with the following paragraph:

[0038] Figure 4. DNA and amino acid sequences of humanized LL1 (hLL1) heavy and light chain variable regions. Figure 4A shows the DNA (SEQ ID NO: 9) and amino acid sequences (SEQ ID NO: 10) of hLL1VH and Figure 4B shows the DNA (SEQ ID NO: 11) and amino acid sequences (SEQ ID NO: 12) of hLL1Vk. Amino acid sequences encoded by the corresponding DNA sequences are given as one letter codes. The amino acid residues in the CDR regions are shown in bold and underlined. Kabat's Ig molecule numbering scheme is used for amino acid residues as in Fig. 1A and Fig. 1B.

Please delete paragraph [0071] and replace it with the following paragraph:

[0071] Where the anti-CD74 antibody is humanized, it may contain CDRs of a light chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence RSSQSLVHRNGNTYLH (SEQ ID NO: 164); a CDR2 including an amino acid sequence TVSNRFS (SEQ ID NO: 172); and a CDR3 including an amino acid sequence SQSSHVPPT (SEQ ID NO: 183)). The humanized anti-CD74 antibody or fragment may include the heavy chain variable region of the humanized mAb, which may include CDRs of a heavy chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence NYGVN (SEQ ID NO: 194); a CDR2 including an amino acid sequence WINPNTGEPTFDDDFKG (SEQ ID NO: 205); and a CDR3 including an amino acid sequence SRGKNEAWFAY (SEQ ID NO: 216)). The humanized anti-CD74 antibody or fragment thereof may include light and heavy chain variable regions including complementarity-determining regions (CDRs) of murine anti-CD74 (mLL1) and the framework (FR) regions of a human antibody, where the light chain variable region of the humanized anti-CD74 mAb includes CDRs of a light chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence RSSQSLVHRNGNTYLH (SEQ ID NO: 164); a CDR2 including an amino acid sequence TVSNRFS (SEQ ID NO: 172); and a CDR3 including an amino acid sequence SQSSHVPPT (SEQ ID NO: 183)), and where the heavy chain variable region of the humanized mAb includes CDRs of a heavy chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence NYGVN (SEQ ID NO: 194); a CDR2 including an amino acid sequence WINPNTGEPTFDDDFKG (SEQ ID NO: 205); and a CDR3 including an amino acid sequence SRGKNEAWFAY (SEQ ID NO: 216)). The humanized anti-CD74 antibody or fragment thereof may include the FRs of the light and heavy chain variable regions of the humanized anti-CD74 antibody or fragment thereof, which may be substituted with at least one amino acid from the corresponding FRs of the murine mAb. In one embodiment, the substituted amino acid may

be selected from amino acid residue 2, 3, 4, 46, 87 and 100 of the murine light chain variable region of the cLL1V_k sequence of Fig. 3B, and amino acid residues 5, 37, 38, 46, 68, 91 and 93 of the murine heavy chain variable region of the cLL1V_H sequence of Fig. 3A. In another embodiment, the mAb or fragment thereof comprises a heavy chain variable region of Fig. 4A and a light chain variable region of Fig. 4B. In a further embodiment, the mAb or fragment thereof may comprise a light and heavy chain constant region of a human antibody or a portion thereof. The mAb or fragment may include a humanized IgG1.

Please delete paragraph [0072] and replace it with the following paragraph:

[0072] Where the anti-CD74 binding molecule includes a chimeric anti-CD74 antibody, the chimeric anti-CD74 antibody or fragment thereof may include a light chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence RSSQSLVHRNGNTYLH (SEQ ID NO:161); a CDR2 including an amino acid sequence TVSNRFS (SEQ ID NO: 172); and a CDR3 including an amino acid sequence SQSSHVPPT (SEQ ID NO: 183)). In another embodiment, the chimeric anti-CD74 antibody or fragment thereof may include a heavy chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence NYGVN (SEQ ID NO: 194); a CDR2 including an amino acid sequence WINPNTGEPTFDDDFKG (SEQ ID NO: 205); and a CDR3 including an amino acid sequence SRGKNEAWFAY (SEQ ID NO: 216)). In a further embodiment, The chimeric anti-CD74 antibody or fragment thereof may include light and heavy chain variable regions which may include complementarity-determining regions (CDRs) of a murine anti-CD74 mAb; the framework (FR) regions of a murine anti-CD 74 mAb; and the light and heavy chain constant regions of a human antibody, where the light chain variable region of the chimeric mAb may include CDRs of a light chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence RSSQSLVHRNGNTYLH (SEQ ID

NO: 164); a CDR2 including an amino acid sequence TVSNRFS (SEQ ID NO: 172); and a CDR3 including an amino acid sequence SQSSHVPPT (SEQ ID NO: 183); and where the heavy chain variable region of the chimeric mAb may include CDRs of a heavy chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence NYGVN (SEQ ID NO: 194); a CDR2 including an amino acid sequence WINPNTGEPTFDDDFKG (SEQ ID NO: 205); and a CDR3 including an amino acid sequence SRGKNEAWFAY (SEQ ID NO: 216)). Alternatively, the chimeric mAb or fragment thereof may include a heavy chain variable region of Fig. 2A and a light chain variable region of Fig. 2B. The chimeric mAb or fragment thereof may include a chimeric IgG1 or fragment thereof.

Please delete paragraph [0073] and replace it with the following paragraph:

[0073] Where the anti-CD74 binding molecule is a human anti-CD74 antibody, the human anti-CD74 antibody or fragment thereof may include a light chain variable region of the human anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence RSSQLVHRNGNTYLH (SEQ ID NO: 164); a CDR2 including an amino acid sequence TVSNRFS (SEQ ID NO: 172); and a CDR3 including an amino acid sequence SQSSHVPPT (SEQ ID NO: 183)). In one embodiment, the human anti-CD74 antibody or fragment thereof may include a heavy chain variable region of the human mAb which may include CDRs of a heavy chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence NYGVN (SEQ ID NO: 194); a CDR2 including an amino acid sequence WINPNTGEPTFDDDFKG (SEQ ID NO: 205); and a CDR3 including an amino acid sequence SRGKNEAWFAY (SEQ ID NO: 216)). In another embodiment, the human anti-CD74 antibody or fragment thereof may include the light and heavy chain variable and constant regions of a human antibody, where the huCD74 CDRs of the light chain variable

region of the human anti-CD74 mAb may include a CDR1 having an amino acid sequence RSSQSLVHRNGNTYLH (SEQ ID NO: 161); a CDR2 having an amino acid sequence TVSNRFS (SEQ ID NO: 172); and a CDR3 having an amino acid sequence SQSSHVPPT (SEQ ID NO: 183); and where the heavy chain variable region of the human mAb may include CDRs of a heavy chain variable region of a murine anti-CD74 mAb (e.g., a CDR1 including an amino acid sequence NYGVN (SEQ ID NO: 194); a CDR2 including an amino acid sequence WINPNTGEPTFDDDFKG (SEQ ID NO: 205); and a CDR3 including an amino acid sequence SRGKNEAWFAY (SEQ ID NO: 216)). The human mAb or fragment thereof may include a human IgG1.